Sebastian Kreuz joined the Boehringer Ingelheim Venture Fund (BIVF) as an investment manager in 2019, focusing on innovative life science investments in Europe. With more than 15 years of experience in translational research and drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities.

Sebastian started his industrial career in 2004 by joining Boehringer Ingelheim (BI) as a research scientist to establish novel experimental platforms based on transcriptomics, RNAi and viral vectors for the exploration of early drug targets. In the following years, Sebastian held various positions within BI’s R&D organization thereby further broadening his drug discovery expertise in early and late-stage projects.

From 2015 to 2019, Sebastian joined BI’s newly formed Research Beyond Borders department to implement a platform concept for viral vector based gene therapy as a novel therapeutic modality for BI. During this time he also established a global collaboration network in the gene therapy space with collaborations in Europe, China and the US.

Sebastian studied Technical Biology in Stuttgart (Germany) and holds a PhD in molecular cell biology and immunology. In addition to Rewind Therapeutics, he serves as a board member for Abalos Therapeutics GmbH, Quantro Therapeutics and Topas Therapeutics GmbH.